Evidence map›Paper›PMID 35256589›Full record

ArticleCell death & disease2022

Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma.

Yuxue Gao, Qingguo Xu, Xinqiang Li, Yuan Guo, Bowen Zhang, Yan Jin, Cunle Zhu, Yuntai Shen, Pengxiang Yang, Ying Shi and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. New insights into T-cell exhaustion in liver cancer: from mechanism to therapy.Journal of cancer research and clinical oncology · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Yuxue GaoBeijing Institute of Hepatology, Capital Medical University, Beijing, 100069, China.
Qingguo XuOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao City, 266003, China.
Xinqiang LiOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao City, 266003, China.
Yuan GuoOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao City, 266003, China.
Bowen ZhangDepartment of Pathology, Inner Mongolia Baogang Hospital, Baotou, 014010, China.
Yan JinOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao City, 266003, China.
Cunle ZhuOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao City, 266003, China.
Yuntai ShenOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao City, 266003, China.
Pengxiang YangBeijing Institute of Hepatology, Capital Medical University, Beijing, 100069, China.
Ying ShiBeijing Institute of Hepatology, Capital Medical University, Beijing, 100069, China.ORCID http://orcid.org/0000-0001-5838-0817
Rifeng JinSchool of Chemical, Biological and Environmental Engineering, Carnegie Mellon University, Corvallis, PA, 97331, USA.
Daojie LiuDepartment of Clinical Laboratory, Haidian Maternal&Child Health Hospital, Beijing, 100080, China.
Yabo OuyangBeijing Institute of Hepatology, Capital Medical University, Beijing, 100069, China.
Xiaoni LiuBeijing Institute of Hepatology, Capital Medical University, Beijing, 100069, China.
Wenjing WangBeijing Institute of Hepatology, Capital Medical University, Beijing, 100069, China.
Dexi ChenBeijing Institute of Hepatology, Capital Medical University, Beijing, 100069, China.ORCID http://orcid.org/0000-0002-6896-6640
Tongwang YangBeijing Institute of Hepatology, Capital Medical University, Beijing, 100069, China. 1203620677@qq.com.ORCID http://orcid.org/0000-0002-6030-8416
Qingdao University · CNCapital Medical University · CNBaogang Group (China) · CNCarnegie Mellon University · USHainan Maternal and Child Health Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor heterogeneity has been associated with immunotherapy and targeted drug resistance in hepatocellular carcinoma (HCC). However, communications between tumor and cytotoxic cells are poorly understood to date. In the present study, thirty-one clusters of cells were discovered in the tumor tissues and adjacent tissues through single-cell sequencing. Moreover, the quantity and function exhaustion of cytotoxic cells was observed to be induced in tumors by the TCR and apoptosis signal pathways. Furthermore, granzyme failure of cytotoxic cells was observed in HCC patients. Importantly, the GZMA secreted by cytotoxic cells was demonstrated to interact with the F2R expressed by the tumor cells both in vivo and in vitro. This interaction induced tumor suppression and T cell-mediated killing of tumor cells via the activation of the JAK2/STAT1 signaling pathway. Mechanistically, the activation of JAK2/STAT1 signaling promoted apoptosis under the mediating effect of the LDPRSFLL motif at the N-terminus of F2R, which interacted with GZMA. In addition, GZMA and F2R were positively correlated with PD-1 and PD-L1 in tumor tissues, while the expressions of F2R and GZMA promoted PD-1 mAb-induced tumor suppression in both mouse model and HCC patients. Finally, in HCC patients, a low expression of GZMA and F2R in the tumor tissues was correlated with aggressive clinicopathological characteristics and poor prognosis. Collectively, GZMA-F2R communication inefficient induces deficient PD-1 mAb therapy and provide a completely novel immunotherapy strategy for tumor suppression in HCC patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsB7-H1 AntigenCell Line, TumorGranzymesHumansImmunotherapyJanus Kinase 2MiceProgrammed Cell Death 1 ReceptorSTAT1 Transcription FactorT-LymphocytesB7-H1 AntigenGranzymesGZMA protein, humanJAK2 protein, humanJanus Kinase 2Programmed Cell Death 1 ReceptorSTAT1 protein, humanStat1 protein, mouseSTAT1 Transcription Factor

Identifiers

PMID35256589
PMCPMC8901912
OpenAlexW4220695318

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.